ICP-248 With Azacitidine
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 266 patients (estimated)
- Tags
- BCL-2 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2226
- NCT Identifier
- NCT06656494
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.